Skip to content
10-K

Annual Report

CTI BIOPHARMA CORP

0000891293-23-000011

← back to feed
Filed
Mar 6, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Feb 21, 2023 131.84M sh
Shares Diluted FY 2022 · Dec 31, 2022 114.69M sh
Shares Diluted FY 2022 · Dec 31, 2021 90.12M sh
Operating Cash Flow FY 2022 · Dec 31, 2022 −$81.19M
Operating Cash Flow FY 2022 · Dec 31, 2021 −$84.89M
Short Term Debt FY 2022 · Dec 31, 2022 $47.94M
Short Term Debt FY 2022 · Dec 31, 2021 $47.38M
Short Term Investments FY 2022 · Dec 31, 2022 $49.52M
Short Term Investments FY 2022 · Dec 31, 2021 $0
Cash And Equivalents FY 2022 · Dec 31, 2022 $30.42M
Cash And Equivalents FY 2022 · Dec 31, 2021 $65.45M
Current Liabilities FY 2022 · Dec 31, 2022 $81.13M
Current Liabilities FY 2022 · Dec 31, 2021 $66.65M
Total Liabilities FY 2022 · Dec 31, 2022 $143.5M
Total Liabilities FY 2022 · Dec 31, 2021 $68.67M
Current Assets FY 2022 · Dec 31, 2022 $99.4M
Current Assets FY 2022 · Dec 31, 2021 $68.38M
Total Assets FY 2022 · Dec 31, 2022 $125.93M
Total Assets FY 2022 · Dec 31, 2021 $72.43M
Eps Diluted FY 2022 · Dec 31, 2022 −$0.81
Eps Diluted FY 2022 · Dec 31, 2021 −$1.09
Eps Basic FY 2022 · Dec 31, 2022 −$0.81
Eps Basic FY 2022 · Dec 31, 2021 −$1.09
Sga Expense FY 2022 · Dec 31, 2022 $84.83M
Sga Expense FY 2022 · Dec 31, 2021 $56.2M
Net Income FY 2022 · Dec 31, 2022 −$92.99M
Net Income FY 2022 · Dec 31, 2021 −$97.91M
Operating Income FY 2022 · Dec 31, 2022 −$79.8M
Operating Income FY 2022 · Dec 31, 2021 −$95.33M
Cost Of Revenue FY 2022 · Dec 31, 2022 $3.51M
Cost Of Revenue FY 2022 · Dec 31, 2021 $0
Revenue FY 2022 · Dec 31, 2022 $53.95M
Revenue FY 2022 · Dec 31, 2021 $0